BioSpace News Archive

Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) – a commercial-stage medical technology company – today reported financial results for its third quarter ended September 30, 2023 and provided a corporate update.

Biohaven Ltd. reported financial results for the third quarter ended September 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference in Miami, FL.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today provides a corporate update for the third quarter ending September 30, 2023.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today provides a corporate update, and reports financial results for the third quarter of 2023 ending September 30, 2023.

Eli Lilly and Company announced that the U.S. NRC has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s radioactive materials license, which will occur following the completion of Lilly’s previously announced tender offer to acquire all of the issued and outstanding shares of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.

Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its first quarter fiscal year 2024 for the period ended September 30, 2023.

Alcon, the global leader in eye care, reported its financial results for the three and nine months ended September 30, 2023.

Inhibikase Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023 and highlighted recent developments.

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates.